{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:49:44Z","timestamp":1776487784540,"version":"3.51.2"},"reference-count":28,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"ISCIIII-FEDER","doi-asserted-by":"publisher","award":["PI17\/00257"],"award-info":[{"award-number":["PI17\/00257"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIIII-FEDER","doi-asserted-by":"publisher","award":["PI21\/01292"],"award-info":[{"award-number":["PI21\/01292"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIIII-FEDER","doi-asserted-by":"publisher","award":["RD16\/0009\/0030"],"award-info":[{"award-number":["RD16\/0009\/0030"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIIII-FEDER","doi-asserted-by":"publisher","award":["RICORS RD21\/0005\/0016"],"award-info":[{"award-number":["RICORS RD21\/0005\/0016"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIIII-FEDER","doi-asserted-by":"publisher","award":["NCI P30 CA016672"],"award-info":[{"award-number":["NCI P30 CA016672"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII-RETICS REDinREN","doi-asserted-by":"publisher","award":["PI17\/00257"],"award-info":[{"award-number":["PI17\/00257"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII-RETICS REDinREN","doi-asserted-by":"publisher","award":["PI21\/01292"],"award-info":[{"award-number":["PI21\/01292"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII-RETICS REDinREN","doi-asserted-by":"publisher","award":["RD16\/0009\/0030"],"award-info":[{"award-number":["RD16\/0009\/0030"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII-RETICS REDinREN","doi-asserted-by":"publisher","award":["RICORS RD21\/0005\/0016"],"award-info":[{"award-number":["RICORS RD21\/0005\/0016"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII-RETICS REDinREN","doi-asserted-by":"publisher","award":["NCI P30 CA016672"],"award-info":[{"award-number":["NCI P30 CA016672"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["PI17\/00257"],"award-info":[{"award-number":["PI17\/00257"]}]},{"name":"National Cancer Institute","award":["PI21\/01292"],"award-info":[{"award-number":["PI21\/01292"]}]},{"name":"National Cancer Institute","award":["RD16\/0009\/0030"],"award-info":[{"award-number":["RD16\/0009\/0030"]}]},{"name":"National Cancer Institute","award":["RICORS RD21\/0005\/0016"],"award-info":[{"award-number":["RICORS RD21\/0005\/0016"]}]},{"name":"National Cancer Institute","award":["NCI P30 CA016672"],"award-info":[{"award-number":["NCI P30 CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2\/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2\u20133-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U\/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs.<\/jats:p>","DOI":"10.3390\/jcm11205977","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T06:13:27Z","timestamp":1665468807000},"page":"5977","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-2052","authenticated-orcid":false,"given":"Mar","family":"Riveiro-Barciela","sequence":"first","affiliation":[{"name":"Liver Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Department of Medicine, Autonomous Univeristy of Barcelona (AUB), 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Autonomous Univeristy of Barcelona (AUB), 08035 Barcelona, Spain"},{"name":"Department of Nephrology, Vall d\u00b4Hebron University Hospital, Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-8939","authenticated-orcid":false,"given":"Ana","family":"Barreira-Diaz","sequence":"additional","affiliation":[{"name":"Liver Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Department of Medicine, Autonomous Univeristy of Barcelona (AUB), 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-4830","authenticated-orcid":false,"given":"Sheila","family":"Bermejo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Autonomous Univeristy of Barcelona (AUB), 08035 Barcelona, Spain"},{"name":"Department of Nephrology, Vall d\u00b4Hebron University Hospital, Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Bruera","sequence":"additional","affiliation":[{"name":"Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S1470-2045(20)30107-8","article-title":"Immune checkpoint inhibitor toxicities: Systems-based approaches to improve patient care and research","volume":"21","author":"Johnson","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure","volume":"66","author":"Wendon","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_10","unstructured":"(2022, May 31). OMERECT: Outcome Measures in Rheumatology Immune-Related Adverse Events Special Interest Group. Available online: https:\\\\omeract.org."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cunningham, M., Iafolla, M., Kanjanapan, Y., Cerocchi, O., Butler, M., Siu, L.L., Bedard, P.L., Ross, K., Hansen, B., and Spreafico, A. (2021). Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253070"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"Michot","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_14","first-page":"5908411","article-title":"Plasmapheresis for Pembrolizumab-Induced Hepatitis in a Patient with Squamous Cell Carcinoma and Prior Orthotopic Liver Transplantation","volume":"2022","author":"Caldis","year":"2022","journal-title":"Case Rep. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","article-title":"Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?","volume":"70","author":"Buti","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area","volume":"34","author":"Mir","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_18","first-page":"318","article-title":"Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis","volume":"16","author":"Moi","year":"2021","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: A case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2215\/CJN.01330213","article-title":"Utility of urine eosinophils in the diagnosis of acute interstitial nephritis","volume":"8","author":"Muriithi","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e002292","DOI":"10.1136\/jitc-2020-002292","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: A single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_23","first-page":"887","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors","volume":"37","author":"Bolufer","year":"2021","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","year":"2019","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/5977\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:49:38Z","timestamp":1760143778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/5977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":28,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11205977"],"URL":"https:\/\/doi.org\/10.3390\/jcm11205977","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]}}}